Navigation Links
Study confirms everolimus can overcome trastuzumab resistance in HER-2 positive early breast cancer
Date:5/2/2013

Lugano-CH, Brussels-BE, 2 May 2013 -- A study that aimed to understand how the cancer drug everolimus helps overcome the resistance breast cancers can develop to trastuzumab has left researchers contemplating a puzzle.

The study showed a statistically non-significant benefit in clinical response rates for some patients with early breast cancer when everolimus was added to treatment with trastuzumab. Yet the results suggest this benefit is achieved independently of the molecular pathways researchers expected would be involved.

Prof Mario Campone, Principal Investigator at Institut Cancerologie de l'Ouest in Nantes, France, presented the findings at the 5th IMPAKT Breast Cancer Conference in Brussels, Belgium. The IMPAKT meeting presents cutting edge, 'translational' breast cancer research that is beginning to have an impact for patients.

"As more targeted cancer drugs are developed, the challenge is to identify which patients will benefit from individual agents," Prof Campone said. "One of the objectives of this study was to determine molecular biomarkers that predict whether a patient's cancer is sensitive to the combination of everolimus and trastuzumab compared to trastuzumab alone."

Trastuzumab is a monoclonal antibody targeted against the HER2 tyrosine kinase receptor. Many patients who initially respond to trastuzumab develop resistance.

In preclinical studies, everolimus, an oral inhibitor of an important molecule called mammalian target of rapamycin (mTOR), has demonstrated an ability to reverse trastuzumab resistance. However, the mechanisms of action involved in the reversion of trastuzumab resistance are not completely understood.

"Resistance to trastuzumab may result from several molecular alterations occurring at different levels of the downstream effectors in the PI3K/AKT pathway, all of them resulting in maintenance of signal transduction," Prof Campone explains. "Therefore, using everolimus to inhibit mTOR, a major downs
'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Study reveals magnitude of variation in gene expression measurements within breast cancers
2. Study opens new prospects for developing new targeted therapies for breast cancer
3. Breast cancer heterogeneity no barrier to predictive testing, study shows
4. BUSM study shows positive impact of mind-body course on well-being of medical students
5. Study finds possible alternative to bariatric weight loss surgery
6. Zebrafish study suggests that vitamin B2 (riboflavin) is an antidote to cyanide poisoning
7. Study examines effects of genetic variants for infants with neonatal abstinence syndrome
8. University of Houston engineering professor awarded grant to study melanoma treatment
9. Monoclonal Antibody with Xencors High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute Lymphoblastic Leukemia
10. BUSM study reveals novel mechanism by which UVA contributes to photoaging of skin
11. Study led by NUS scientists reveals escalating cost of forest conservation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/4/2014)... 4, 2014   Neurotechnology , a provider ... the latest version of its fingerprint matching algorithm ... MINEX evaluation organized by NIST. The MINEX ... the INCITS 378 fingerprint standard template format. MINEX ... tenders in the United States ...
(Date:11/3/2014)... study published in this month,s Proceedings of ... of a recently discovered communication molecule of the body,s ... known to limit inflammation and the current study reports ... the ability of the immune system to recognize and ... IL-37,s effect on the immune system now allows us ...
(Date:11/3/2014)... weight and preterm birth are linked to increased risk ... in the American College of Rheumatology (ACR) journal, ... weight and pre-term babies were not at greater risk ... , According to the ACR, 27 million Americans over ... Symptoms of OA range from mild to severe and ...
Breaking Biology News(10 mins):Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3PNAS: From HIV to cancer, IL-37 regulates immune system 2Preterm, low birth-weight babies may need new hips in adulthood 2
... who have adapted a three-dimensional, general circulation model of ... ago when the sun was significantly fainter than present ... catastrophic glaciation than previously believed. The new 3-D ... from about 3.8 billion years to 2.5 billion years ...
... Managing commercial and recreational fisheries is a complex ... and regulatory agencies don,t always see eye-to-eye. Researchers ... now working with commercial fishermen to collect and share ... build trust and foster the mutual goal of sustainable ...
... neurodegenerative diseases such as Parkinson,s and Alzheimer,s, cancer and ... partially caused or accelerated by oxidative stress. Oxidative stress ... what are called reactive oxygen species (ROS). "However, up ... changes in a living organism and certainly not how ...
Cached Biology News:Early Earth may have been prone to deep freezes, says CU-Boulder study 2Early Earth may have been prone to deep freezes, says CU-Boulder study 3Public-private partnership helps monitor fish populations 2Public-private partnership helps monitor fish populations 3Public-private partnership helps monitor fish populations 4Public-private partnership helps monitor fish populations 5Oxidative stress: Less harmful than suspected? 2
(Date:11/26/2014)... Chester, OH (PRWEB) November 25, 2014 ... Holdings, has joined the Graphel Carbon Products team as ... in sales, marketing, and customer service for the graphite ... add Miles to our team,” stated Dave Trinkley, VP ... “His wide range of experience in the graphite ...
(Date:11/26/2014)... , 25 novembre 2014 Theravalues Corporation ... sur le marché européen au salon Hi Europe ... Amsterdam ). Curcumine la plus ... technologie amorphe (non-cristalline) à des ingrédients approuvés par ... un pigment jaune présent dans la racine de ...
(Date:11/24/2014)... BUENA, N.J. , Nov. 24, 2014  IGI ... Jersey based specialty generic pharmaceutical company, today ... application (ANDA) to the U.S. Food and Drug Administration ... submissions in 2014 to seven, with eighteen submissions now ... Grenfell-Gardner , President and CEO of the Company, commented, ...
(Date:11/24/2014)... November 24, 2014   ... ScienceDirect   Elsevier , a world-leading provider ... pleased to announce the launch of the latest title in ... Current Opinion in Food Science . ... specialists with a new platform to keep up-to-date with the ...
Breaking Biology Technology:Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3IGI Laboratories, Inc. Announces ANDA Submission 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 3
... Brings Both Clinical Trial Experience and Business ... Role, CAMBRIDGE, Mass., Jan. 16 Cytel, ... executive Irving Dark has,accepted the role of Vice ... to Cytel 15-years of management experience guiding drug,biologic ...
... BASEL, Switzerland, Jan. 16 Roche (OTCQX:,RHHBY; SWX: ROG.VX; ... today that it has extended its,offer to acquire all ... (Nasdaq: VMSI ) to 5:00 p.m., New York ... was previously scheduled to expire at 5:00,p.m., New York ...
... NEW YORK, Jan. 16 With the field ... research, the Society for Biological Engineering,(SBE) has organized ... conference, which runs from January 20th to 23rd ... will focus on,engineering designs for stem cell production, ...
Cached Biology Technology:Irving Dark Named Vice President of Cytel Clinical Research Services 2Roche Extends Tender Offer for Ventana 2Roche Extends Tender Offer for Ventana 3Roche Extends Tender Offer for Ventana 4Roche Extends Tender Offer for Ventana 5Society for Biological Engineering Holds First International Conference on Stem Cell Engineering 2
... Panels were designed for full-length gene cloning ... to identify the desired cDNA clone. The ... 96-well "Master Plate," where each well contains ... the positive well(s) by gel electrophoresis of ...
... Preparation Note: Prepared by a ... C.W., et al., Biotechnol. Bioeng., ... Definition: One unit will yield an ... 1.0 ml of water (1 cm ...
... Dithiothreitol DTT White solid.. ... disulfides to thiols, so reaction is "driven" to ... not contain waxy surfactant found in many other ... pentobarbitol. Purity: ≥97% by titration. ...
... Basically, most ``special`` dye stains are ... few other non-routine) stains are $9.00. ... a paraffin block, staining, coverslipping and ... (for senile plaques) ,Bodian`s Stain ,Copper ...
Biology Products: